Compare GABC & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GABC | ORKA |
|---|---|---|
| Founded | 1910 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | N/A | N/A |
| Metric | GABC | ORKA |
|---|---|---|
| Price | $39.92 | $28.50 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | $45.50 | ★ $48.20 |
| AVG Volume (30 Days) | 145.0K | ★ 660.6K |
| Earning Date | 01-26-2026 | 11-12-2025 |
| Dividend Yield | ★ 2.90% | N/A |
| EPS Growth | ★ 3.79 | N/A |
| EPS | ★ 2.87 | N/A |
| Revenue | ★ $312,775,000.00 | N/A |
| Revenue This Year | $47.67 | N/A |
| Revenue Next Year | $6.23 | N/A |
| P/E Ratio | $13.90 | ★ N/A |
| Revenue Growth | ★ 26.55 | N/A |
| 52 Week Low | $32.75 | $5.49 |
| 52 Week High | $43.20 | $32.64 |
| Indicator | GABC | ORKA |
|---|---|---|
| Relative Strength Index (RSI) | 46.80 | 44.71 |
| Support Level | $39.82 | $30.31 |
| Resistance Level | $40.27 | $32.64 |
| Average True Range (ATR) | 0.61 | 2.09 |
| MACD | -0.15 | -0.18 |
| Stochastic Oscillator | 10.76 | 15.83 |
German American Bancorp Inc is a bank holding company. The lines of business include Retail and commercial banking business which involves attracting deposits from the general public and using those funds to originate consumer, commercial and agricultural, commercial and agricultural real estate, and residential mortgage loans. These core banking activities also include the sale of residential mortgage loans in the secondary market. Wealth management services which involve providing trust, investment advisory, brokerage and retirement planning services to customers. Insurance operations include the offering of a full range of personal and corporate property and casualty insurance products.
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.